Technical Analysis for NXL - Nexalin Technology, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.18% | |
| Overbought Stochastic | Strength | 0.18% | |
| Down 3 Days in a Row | Weakness | 0.18% | |
| NR7 | Range Contraction | -1.88% | |
| Inside Day | Range Contraction | -1.88% | |
| Wide Bands | Range Expansion | -1.88% | |
| Overbought Stochastic | Strength | -1.88% | |
| Wide Bands | Range Expansion | -2.13% | |
| Overbought Stochastic | Strength | -2.13% | |
| New 52 Week Closing High | Bullish | -9.79% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 2 hours ago |
| Rose Above 10 DMA | about 2 hours ago |
| Up 1% | about 2 hours ago |
| Down 2 % | about 2 hours ago |
| Down 1% | about 2 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Sector: Healthcare
Industry: Medical Devices
Keywords: Neuroscience Alzheimer's Disease Mental Health Chronic Pain Dementia Psychiatric Diagnosis Psychiatry Insomnia Mental Disorder Neurostimulation Mental Health Disorders
Classification
Sector: Healthcare
Industry: Medical Devices
Keywords: Neuroscience Alzheimer's Disease Mental Health Chronic Pain Dementia Psychiatric Diagnosis Psychiatry Insomnia Mental Disorder Neurostimulation Mental Health Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.36 |
| 52 Week Low | 0.2528 |
| Average Volume | 1,899,678 |
| 200-Day Moving Average | 1.27 |
| 50-Day Moving Average | 1.77 |
| 20-Day Moving Average | 3.19 |
| 10-Day Moving Average | 3.81 |
| Average True Range | 0.52 |
| RSI (14) | 65.16 |
| ADX | 49.69 |
| +DI | 25.54 |
| -DI | 13.67 |
| Chandelier Exit (Long, 3 ATRs) | 2.80 |
| Chandelier Exit (Short, 3 ATRs) | 2.69 |
| Upper Bollinger Bands | 4.57 |
| Lower Bollinger Band | 1.82 |
| Percent B (%b) | 0.72 |
| BandWidth | 86.16 |
| MACD Line | 0.66 |
| MACD Signal Line | 0.66 |
| MACD Histogram | 0.0043 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.38 | ||||
| Resistance 3 (R3) | 4.39 | 4.21 | 4.28 | ||
| Resistance 2 (R2) | 4.21 | 4.07 | 4.21 | 4.25 | |
| Resistance 1 (R1) | 4.01 | 3.98 | 3.92 | 3.99 | 4.22 |
| Pivot Point | 3.83 | 3.83 | 3.78 | 3.82 | 3.83 |
| Support 1 (S1) | 3.62 | 3.68 | 3.53 | 3.61 | 3.38 |
| Support 2 (S2) | 3.44 | 3.59 | 3.44 | 3.35 | |
| Support 3 (S3) | 3.24 | 3.44 | 3.32 | ||
| Support 4 (S4) | 3.22 |
